Related Experiment Video
Updated: Apr 17, 2026

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
Published on: August 20, 2007
Reimbursement programs and health technology assessment for diabetes devices and supplies: a Canadian perspective
Richard Y Cheung1, Vanessa Mui2
1Fasken Martineau DuMoulin LLP, Toronto, Ontario, Canada rcheung@fasken.com.
Abstract:
The reimbursement model for medical devices and supplies used in the management of diabetes in Canada, along with the process for assessing new health technologies, can be complicated. Various provincial programs, including Ontario's Assistive Devices Program and the Ontario Monitoring for Health Program, reimburse the costs associated with certain devices and supplies for diabetes management. In addition, provincial advisory committees, such as the Ontario Health Technology Advisory Committee, review and make recommendations on the adoption of new health technologies in each province. This article provides an overview of the reimbursement programs available for diabetes devices and supplies and reviews the process for assessing new health technologies using the province of Ontario as an example.
Related Concept Videos
Health Information Technology and Healthcare Information System
Health Information Technology, commonly called HIT, integrates advanced information systems and technology in healthcare settings. Its primary functions include:
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Issues And Trends In Healthcare Delivery System
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Heart Failure VI: Adjunct Therapies
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

